000			02292 a2200661 4500
005			20250514015356.0
264		0	_c20011214
008			200112s 0 0 eng d
022			_a0268-3369
024	7		_a10.1038/sj.bmt.1703215 _2doi
040			_aNLM _beng _cNLM
100	1		_aKröger, N
245	0	0	_aA fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. _h[electronic resource]
260			_bBone marrow transplantation _cOct 2001
300			_a643-7 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdult
650	0	4	_aAnemia, Refractory, with Excess of Blasts _xgenetics
650	0	4	_aAntilymphocyte Serum _xadministration & dosage
650	0	4	_aBone Marrow _xpathology
650	0	4	_aBusulfan _xadministration & dosage
650	0	4	_aCell Count
650	0	4	_aChromosomes, Human, Pair 7 _xgenetics
650	0	4	_aCyclophosphamide _xadministration & dosage
650	0	4	_aDisease-Free Survival
650	0	4	_aFeasibility Studies
650	0	4	_aGraft Survival
650	0	4	_aGraft vs Host Disease _xmortality
650	0	4	_aHematopoietic Stem Cell Transplantation
650	0	4	_aHepatic Veno-Occlusive Disease _xetiology
650	0	4	_aHistocompatibility
650	0	4	_aHumans
650	0	4	_aInfections _xetiology
650	0	4	_aKaryotyping
650	0	4	_aMethotrexate _xadministration & dosage
650	0	4	_aMiddle Aged
650	0	4	_aMonosomy
650	0	4	_aMyelodysplastic Syndromes _xgenetics
650	0	4	_aRecurrence
650	0	4	_aSurvival Rate
650	0	4	_aT-Lymphocytes
650	0	4	_aTissue Donors
650	0	4	_aTransplantation Conditioning _xadverse effects
650	0	4	_aTransplantation, Homologous
650	0	4	_aTreatment Outcome
650	0	4	_aVidarabine _xadministration & dosage
700	1		_aSchetelig, J
700	1		_aZabelina, T
700	1		_aKrüger, W
700	1		_aRenges, H
700	1		_aStute, N
700	1		_aSchrum, J
700	1		_aKabisch, H
700	1		_aSiegert, W
700	1		_aZander, A R
773	0		_tBone marrow transplantation _gvol. 28 _gno. 7 _gp. 643-7
856	4	0	_uhttps://doi.org/10.1038/sj.bmt.1703215 _zAvailable from publisher's website
999			_c11619816 _d11619816